Literature DB >> 22946843

In vitro optimization of EtNBS-PDT against hypoxic tumor environments with a tiered, high-content, 3D model optical screening platform.

Oliver J Klein1, Brijesh Bhayana, Yong Jin Park, Conor L Evans.   

Abstract

Hypoxia and acidosis are widely recognized as major contributors to the development of treatment resistant cancer. For patients with disseminated metastatic lesions, such as most women with ovarian cancer (OvCa), the progression to treatment resistant disease is almost always fatal. Numerous therapeutic approaches have been developed to eliminate treatment resistant carcinoma, including novel biologic, chemo, radiation, and photodynamic therapy (PDT) regimens. Recently, PDT using the cationic photosensitizer EtNBS was found to be highly effective against therapeutically unresponsive hypoxic and acidic OvCa cellular populations in vitro. To optimize this treatment regimen, we developed a tiered, high-content, image-based screening approach utilizing a biologically relevant OvCa 3D culture model to investigate a small library of side-chain modified EtNBS derivatives. The uptake, localization, and photocytotoxicity of these compounds on both the cellular and nodular levels were observed to be largely mediated by their respective ethyl side chain chemical alterations. In particular, EtNBS and its hydroxyl-terminated derivative (EtNBS-OH) were found to have similar pharmacological parameters, such as their nodular localization patterns and uptake kinetics. Interestingly, these two molecules were found to induce dramatically different therapeutic outcomes: EtNBS was found to be more effective in killing the hypoxic, nodule core cells with superior selectivity, while EtNBS-OH was observed to trigger widespread structural degradation of nodules. This breakdown of the tumor architecture can improve the therapeutic outcome and is known to synergistically enhance the antitumor effects of front-line chemotherapeutic regimens. These results, which would not have been predicted or observed using traditional monolayer or in vivo animal screening techniques, demonstrate the powerful capabilities of 3D in vitro screening approaches for the selection and optimization of therapeutic agents for the targeted destruction of specific cellular subpopulations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22946843      PMCID: PMC3538815          DOI: 10.1021/mp300262x

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  48 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini.

Authors:  Jayanta Debnath; Kenna R Mills; Nicole L Collins; Mauricio J Reginato; Senthil K Muthuswamy; Joan S Brugge
Journal:  Cell       Date:  2002-10-04       Impact factor: 41.582

Review 3.  Dissecting tumour pathophysiology using intravital microscopy.

Authors:  Rakesh K Jain; Lance L Munn; Dai Fukumura
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

4.  Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells.

Authors:  M H Teiten; L Bezdetnaya; J L Merlin; C Bour-Dill; M E Pauly; M Dicato; F Guillemin
Journal:  J Photochem Photobiol B       Date:  2001-09-15       Impact factor: 6.252

Review 5.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.

Authors:  M Höckel; P Vaupel
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

6.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.

Authors:  Ian F Tannock; Carol M Lee; Jonathon K Tunggal; David S M Cowan; Merrill J Egorin
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

7.  Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis.

Authors:  Manuela Reichert; Joachim P Steinbach; Petra Supra; Michael Weller
Journal:  Cancer       Date:  2002-09-01       Impact factor: 6.860

8.  Comparison of chemosensitivity tests: clonogenic assay versus MTT assay.

Authors:  Kazuhiko Kawada; Toshiro Yonei; Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Nagio Takigawa; Mine Harada; Mitsune Tanimoto
Journal:  Acta Med Okayama       Date:  2002-06       Impact factor: 0.892

Review 9.  Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.

Authors:  Aoife M Shannon; David J Bouchier-Hayes; Claire M Condron; Deirdre Toomey
Journal:  Cancer Treat Rev       Date:  2003-08       Impact factor: 12.111

10.  Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay--a comparative study.

Authors:  Karl Buch; Tanja Peters; Thomas Nawroth; Markus Sänger; Heinz Schmidberger; Peter Langguth
Journal:  Radiat Oncol       Date:  2012-01-03       Impact factor: 3.481

View more
  15 in total

Review 1.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

2.  Toward a 3D cellular model for studying in vitro the outcome of photodynamic treatments: accounting for the effects of tissue complexity.

Authors:  Mireia Alemany-Ribes; María García-Díaz; Marta Busom; Santi Nonell; Carlos E Semino
Journal:  Tissue Eng Part A       Date:  2013-04-19       Impact factor: 3.845

3.  Longitudinal, quantitative monitoring of therapeutic response in 3D in vitro tumor models with OCT for high-content therapeutic screening.

Authors:  O J Klein; Y K Jung; C L Evans
Journal:  Methods       Date:  2013-09-03       Impact factor: 3.608

4.  Structure-function relationships of Nile blue (EtNBS) derivatives as antimicrobial photosensitizers.

Authors:  Daniela Vecchio; Brijesh Bhayana; Liyi Huang; Elisa Carrasco; Conor L Evans; Michael R Hamblin
Journal:  Eur J Med Chem       Date:  2014-02-01       Impact factor: 6.514

Review 5.  High-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional models.

Authors:  Natalia J Martinez; Steven A Titus; Amanda K Wagner; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2015-09-22       Impact factor: 6.098

6.  Quantitative Proteomic and Phosphoproteomic Comparison of 2D and 3D Colon Cancer Cell Culture Models.

Authors:  Xiaoshan Yue; Jessica K Lukowski; Eric M Weaver; Susan B Skube; Amanda B Hummon
Journal:  J Proteome Res       Date:  2016-10-10       Impact factor: 4.466

7.  Label-Free, Longitudinal Visualization of PDT Response In Vitro with Optical Coherence Tomography.

Authors:  Yookyung Jung; Alexander J Nichols; Oliver J Klein; Emmanuel Roussakis; Conor L Evans
Journal:  Isr J Chem       Date:  2012-09-13       Impact factor: 3.333

Review 8.  Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.

Authors:  Demian van Straten; Vida Mashayekhi; Henriette S de Bruijn; Sabrina Oliveira; Dominic J Robinson
Journal:  Cancers (Basel)       Date:  2017-02-18       Impact factor: 6.639

9.  Photodynamic therapy with decacationic [60]fullerene monoadducts: effect of a light absorbing electron-donor antenna and micellar formulation.

Authors:  Rui Yin; Min Wang; Ying-Ying Huang; Huang-Chiao Huang; Pinar Avci; Long Y Chiang; Michael R Hamblin
Journal:  Nanomedicine       Date:  2013-12-10       Impact factor: 5.307

10.  Longitudinal, label-free, quantitative tracking of cell death and viability in a 3D tumor model with OCT.

Authors:  Yookyung Jung; Oliver J Klein; Hequn Wang; Conor L Evans
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.